Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
Category: #health  By Mateen Dalal  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
  • INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.  
     
  • Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first six months of 2020.

Inhibrx Inc., an international biotechnology company founded in 2010 aimed at developing a pipeline of new biologic therapeutic candidates, reportedly announced the registration of first patient in its Phase 1 clinical trial of a therapeutic candidate INBRX-101 (NCT03815396).

NCT03815396 is a therapeutic candidate based on Fc-fusion protein which comprises improved recombinant iterations of human alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency, commonly called AATD, in patients.

AATD is a rare respiratory disease that is characterized by continuous impairment of lung tissue which leads to emphysema and COPD. Reports cite, approx. 100,000 people are affected by this disease across the United States with Europe numbers being at the same approximate level.

Plasma derived augmentation therapy (pdAAT), present standard of care of patients affected with AATD, has remained unchanged for several decades and depends on the weekly infusions of AAT derived from plasma purified from the human donor serum.

The company’s therapeutic candidate INBRX-101 is developed to provide greater clinical activity into pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.   

CEO of Inhibrx, Mark Lappe stated that the company applied its protein engineering capabilities for overcoming the challenges associated with producing functional recombinant human alpha-1 antitrypsin, apart from identifying modifications that the company believes to be capable to optimize PK functionality and profile. Mark further added that the company is thrilled to start enrollment of Phase 1 trial to assess the potential advantages of INBRX-101 in individuals affected by AATD.

Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first 6 months of 2020.

 

Source credit: https://inhibrx.com/inhibrx-announces-enrollment-of-first-patient-in-phase-1-study-of-inbrx-101-a-modified-recombinant-human-aat-fc-fusion-protein/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...